濟民製藥(603222.SH)三跌停後開板,迴應莊家忽悠散户接盤:公司沒參與
格隆匯6月17日丨已連續三日一字跌停的濟民製藥(603222.SH)今日終於開板,盤中一度跌停,目前跌幅收窄至5.96%,報36.6元,最新總市值117億元。該股於6月11日創出歷史新高價57.43元后大肆回落,隨後連續三日跌停。從最高價57.43元跌至今日盤中的最低價35.03元,最大跌幅達39%。濟民製藥公告,近日收到多位投資者反映,市場上存在有人利用微信羣、QQ羣及直播間向股民推薦買入濟民製藥股票的情形。濟民製藥表示,經公司、控股股東、實際控制人、董事、監事及高級管理人自查,各方均未策劃、參與該事件,亦未授意他人策劃、參與該事件,與該事件無任何關聯關係。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.